ArticleJournal of acquired immune deficiency syndromes (1999)2015
GSK1265744 demonstrates robust in vitro activity against various clades of HIV-1.
Article in Journal of acquired immune deficiency syndromes (1999), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults.The Journal of antimicrobial chemotherapy · 2020Trial
- Effect of a High-Fat Meal on the Pharmacokinetics of the HIV Integrase Inhibitor Cabotegravir.Clinical pharmacology in drug development · 2019Trial
- Dynamic changes of monocytes-related immune activation in people with HIV switching to long-acting injectable cabotegravir plus rilpivirine.Scientific reports · 2026Article
- Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention.Infection & chemotherapy · 2021Review
- Quantum Mechanical-Based Stability Evaluation of Crystal Structures for HIV-Targeted Drug Cabotegravir.Molecules (Basel, Switzerland) · 2021Article
- Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.AIDS (London, England) · 2021Article
- Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study.ACS pharmacology & translational science · 2021Article
- Long-acting injectable cabotegravir for the prevention of HIV infection.Current opinion in HIV and AIDS · 2020Review
- Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection.Nature communications · 2019Article
- Pharmacokinetic testing of a first-generation cabotegravir prodrug in rhesus macaques.AIDS (London, England) · 2019Article
- Article
- Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes.AIDS (London, England) · 2018Article
- Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.Biomaterials · 2018Article
- Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date.HIV/AIDS (Auckland, N.Z.) · 2016Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.